Inspire Medical Systems (INSP) shares plunged 5.86% in pre-market trading on Tuesday, February 11, 2025, after multiple analysts lowered their price targets on the stock.
Truist Securities cut its price target on INSP to $235 from $250, though it maintained a Buy rating on the medical device company. Meanwhile, Wells Fargo also reduced its price target on INSP to $195 from $198.
The downward revisions in analysts' price targets appear to be the primary reason behind INSP's pre-market sell-off, as investors reacted negatively to the lowered expectations for the stock's future performance.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。